TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Cardiovascular Training on Fitness, Cardiovascular Health, Bone Health and Quality of Life in Individuals With Ankylosing Spondylitis
Brief Summary: To test the effects of a cardiovascular training compared to attention control in a group of AS-patients participating in classic spinal mobility exercise groups (randomized controlled trial)


Options:
A: Arm Label: Exercise group; Type: EXPERIMENTAL; Interventions: Behavioral: Exercise | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise group
B: Arm Label: Exercise Group; Type: EXPERIMENTAL; Interventions: Other: Exercise | Arm Label: Control Group; Type: OTHER; Interventions: Other: Drug treatment | Intervention Type: OTHER; Name: Exercise; Assigned to Arm(s): Exercise Group | Intervention Type: OTHER; Name: Drug treatment; Assigned to Arm(s): Control Group
C: Arm Label: Back pain / peripheral arthritis; Type: N/A; Interventions: N/A
D: Arm Label: Training; Type: EXPERIMENTAL; Interventions: Behavioral: Cardiovascular Training | Intervention Type: BEHAVIORAL; Name: Cardiovascular Training; Assigned to Arm(s): Training

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Negative Appendectomy Rate Following Low-dose CT vs. Standard-dose CT
Brief Summary: The purpose of this study is to determine whether low-dose CT is not inferior to standard-dose CT in the rate of unnecessary appendectomy.


Options:
A: Arm Label: Low-dose CT; Type: EXPERIMENTAL; Interventions: Radiation: Diagnostic CT | Arm Label: Standard-dose CT; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Diagnostic CT | Intervention Type: RADIATION; Name: Diagnostic CT; Assigned to Arm(s): Low-dose CT | Intervention Type: RADIATION; Name: Diagnostic CT; Assigned to Arm(s): Standard-dose CT
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Omnipaque | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Omnipaque | Intervention Type: OTHER; Name: Omnipaque; Assigned to Arm(s): 1, 2
C: Arm Label: Operative treatment; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Appendicectomy | Arm Label: Antibiotic treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ertapenem | Intervention Type: PROCEDURE; Name: Appendicectomy; Assigned to Arm(s): Operative treatment | Intervention Type: DRUG; Name: Ertapenem; Assigned to Arm(s): Antibiotic treatment
D: Arm Label: Diagnostic imaging; Type: EXPERIMENTAL; Interventions: Procedure: Diagnostic imaging | Arm Label: Repeat examination after observation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Diagnostic imaging | Intervention Type: PROCEDURE; Name: Diagnostic imaging; Assigned to Arm(s): Diagnostic imaging, Repeat examination after observation

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Negative Appendectomy Rate Following Low-dose CT vs. Standard-dose CT
Brief Summary: The purpose of this study is to determine whether low-dose CT is not inferior to standard-dose CT in the rate of unnecessary appendectomy.


Options:
A: Arm Label: Antibiotics Therapy Arm; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin | Arm Label: Appendectomy Arm; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Appendectomy | Intervention Type: DRUG; Name: Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin; Assigned to Arm(s): Antibiotics Therapy Arm | Intervention Type: PROCEDURE; Name: Appendectomy; Assigned to Arm(s): Appendectomy Arm
B: Arm Label: Low-dose CT; Type: EXPERIMENTAL; Interventions: Diagnostic Test: Diagnostic CT with low-dose radiation | Arm Label: Standard-dose CT; Type: ACTIVE_COMPARATOR; Interventions: Diagnostic Test: Diagnostic CT with standard-dose radiation | Intervention Type: DIAGNOSTIC_TEST; Name: Diagnostic CT with low-dose radiation; Assigned to Arm(s): Low-dose CT | Intervention Type: DIAGNOSTIC_TEST; Name: Diagnostic CT with standard-dose radiation; Assigned to Arm(s): Standard-dose CT
C: Arm Label: Low-dose CT; Type: EXPERIMENTAL; Interventions: Radiation: Diagnostic CT | Arm Label: Standard-dose CT; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Diagnostic CT | Intervention Type: RADIATION; Name: Diagnostic CT; Assigned to Arm(s): Low-dose CT | Intervention Type: RADIATION; Name: Diagnostic CT; Assigned to Arm(s): Standard-dose CT
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: appendectomy | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: amoxicillin/clavulanate potassium | Intervention Type: DRUG; Name: amoxicillin/clavulanate potassium; Assigned to Arm(s): B | Intervention Type: PROCEDURE; Name: appendectomy; Assigned to Arm(s): A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 3-Phase Study to Evaluate Sustained Remission and Productivity Outcomes in Subjects With Early Rheumatoid Arthritis Initiated on Treatment With Etanercept Plus Methotrexate
Brief Summary: Study to evaluate whether there is sustained remission and productivity in subjects with early rheumatoid arthritis started on etanercept plus methotrexate treatment.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3
B: Arm Label: 1-M : Maintenance; Type: ACTIVE_COMPARATOR; Interventions: Drug: DMARD maintenance | Arm Label: 2 -S : Spacing of TNF-blocker injections; Type: EXPERIMENTAL; Interventions: Drug: progressive spacing of TNF-blocker injections | Intervention Type: DRUG; Name: progressive spacing of TNF-blocker injections; Assigned to Arm(s): 2 -S : Spacing of TNF-blocker injections | Intervention Type: DRUG; Name: DMARD maintenance; Assigned to Arm(s): 1-M : Maintenance
C: Arm Label: Adalimumab 40 mg eow; Type: EXPERIMENTAL; Interventions: Biological: Adalimumab | Arm Label: Adalimumab Tapering; Type: ACTIVE_COMPARATOR; Interventions: Biological: Adalimumab | Arm Label: Adalimumab Withdrawal Arm; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: Adalimumab 40 mg eow Rescue Arm; Type: EXPERIMENTAL; Interventions: Biological: Adalimumab | Intervention Type: BIOLOGICAL; Name: Adalimumab; Assigned to Arm(s): Adalimumab 40 mg eow, Adalimumab 40 mg eow Rescue Arm, Adalimumab Tapering | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Adalimumab Withdrawal Arm
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: etanercept | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 3-Phase Study to Evaluate Sustained Remission and Productivity Outcomes in Subjects With Early Rheumatoid Arthritis Initiated on Treatment With Etanercept Plus Methotrexate
Brief Summary: Study to evaluate whether there is sustained remission and productivity in subjects with early rheumatoid arthritis started on etanercept plus methotrexate treatment.


Options:
A: Arm Label: Tocilizumab 8 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Tocilizumab, Drug: Placebo to adalimumab | Arm Label: Adalimumab 40 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Adalimumab, Drug: Placebo to tocilizumab | Intervention Type: DRUG; Name: Tocilizumab; Assigned to Arm(s): Tocilizumab 8 mg/kg | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): Adalimumab 40 mg | Intervention Type: DRUG; Name: Placebo to tocilizumab; Assigned to Arm(s): Adalimumab 40 mg | Intervention Type: DRUG; Name: Placebo to adalimumab; Assigned to Arm(s): Tocilizumab 8 mg/kg
B: Arm Label: Placebo followed by Certolizumab Pegol (CZP); Type: OTHER; Interventions: Other: Placebo, Biological: Certolizumab Pegol (CZP) 200 mg, Biological: Certolizumab Pegol (CZP) 400 mg | Arm Label: Certolizumab Pegol (CZP); Type: EXPERIMENTAL; Interventions: Biological: Certolizumab Pegol (CZP) 200 mg, Biological: Certolizumab Pegol (CZP) 400 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo followed by Certolizumab Pegol (CZP) | Intervention Type: BIOLOGICAL; Name: Certolizumab Pegol (CZP) 200 mg; Assigned to Arm(s): Certolizumab Pegol (CZP), Placebo followed by Certolizumab Pegol (CZP) | Intervention Type: BIOLOGICAL; Name: Certolizumab Pegol (CZP) 400 mg; Assigned to Arm(s): Certolizumab Pegol (CZP), Placebo followed by Certolizumab Pegol (CZP)
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: etanercept | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): 1
D: Arm Label: Abatacept; Type: EXPERIMENTAL; Interventions: Drug: Abatacept | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 3-Phase Study to Evaluate Sustained Remission and Productivity Outcomes in Subjects With Early Rheumatoid Arthritis Initiated on Treatment With Etanercept Plus Methotrexate
Brief Summary: Study to evaluate whether there is sustained remission and productivity in subjects with early rheumatoid arthritis started on etanercept plus methotrexate treatment.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1, 2, 3
B: Arm Label: Tocilizumab + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: methotrexate | Arm Label: Tocilizumab + Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: placebo | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): Tocilizumab + Methotrexate, Tocilizumab + Placebo | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): Tocilizumab + Methotrexate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Tocilizumab + Placebo
C: Intervention Type: DRUG; Name: CDP870; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: etanercept | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): 1

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 3-Phase Study to Evaluate Sustained Remission and Productivity Outcomes in Subjects With Early Rheumatoid Arthritis Initiated on Treatment With Etanercept Plus Methotrexate
Brief Summary: Study to evaluate whether there is sustained remission and productivity in subjects with early rheumatoid arthritis started on etanercept plus methotrexate treatment.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: methotrexate, Drug: etanercept | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: methotrexate, Drug: sulfasalazine, Drug: hydroxychloroquine | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: methotrexate, Drug: etanercept | Arm Label: 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: methotrexate, Drug: sulfasalazine, Drug: hydroxychloroquine | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): 1, 2, 3, 4 | Intervention Type: DRUG; Name: sulfasalazine; Assigned to Arm(s): 2, 4 | Intervention Type: DRUG; Name: hydroxychloroquine; Assigned to Arm(s): 2, 4 | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): 1, 3
B: Arm Label: Group I: Placebo + Methotrexate (MTX); Type: EXPERIMENTAL; Interventions: Drug: Golimumab, Other: Placebo, Drug: methotrexate (MTX) | Arm Label: Group II: Golimumab + Methotrexate (MTX); Type: PLACEBO_COMPARATOR; Interventions: Drug: Golimumab, Other: Placebo, Drug: methotrexate (MTX) | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): Group I: Placebo + Methotrexate (MTX), Group II: Golimumab + Methotrexate (MTX) | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Group I: Placebo + Methotrexate (MTX), Group II: Golimumab + Methotrexate (MTX) | Intervention Type: DRUG; Name: methotrexate (MTX); Assigned to Arm(s): Group I: Placebo + Methotrexate (MTX), Group II: Golimumab + Methotrexate (MTX)
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: etanercept | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): 1
D: Arm Label: ETN Alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: ETN Alone | Arm Label: ETN+MTX; Type: ACTIVE_COMPARATOR; Interventions: Drug: ETN+MTX | Intervention Type: DRUG; Name: ETN Alone; Assigned to Arm(s): ETN Alone | Intervention Type: DRUG; Name: ETN+MTX; Assigned to Arm(s): ETN+MTX

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A 3-Phase Study to Evaluate Sustained Remission and Productivity Outcomes in Subjects With Early Rheumatoid Arthritis Initiated on Treatment With Etanercept Plus Methotrexate
Brief Summary: Study to evaluate whether there is sustained remission and productivity in subjects with early rheumatoid arthritis started on etanercept plus methotrexate treatment.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: etanercept | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): 1
B: Arm Label: 5 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 15 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: 30 mg BID; Type: EXPERIMENTAL; Interventions: Drug: CP-690,550 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 5 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 15 mg BID | Intervention Type: DRUG; Name: CP-690,550; Assigned to Arm(s): 30 mg BID | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Group I: 2mg/kg Golimumab + MTX; Type: EXPERIMENTAL; Interventions: Drug: Golimumab, Drug: Methotrexate | Arm Label: Group II: 2mg/kg Golimumab only; Type: EXPERIMENTAL; Interventions: Drug: Golimumab, Drug: Placebo | Arm Label: Group III: 4mg/kg Golimumab + MTX; Type: EXPERIMENTAL; Interventions: Drug: Golimumab, Drug: Methotrexate | Arm Label: Group IV: 4mg/kg Golimumab only; Type: EXPERIMENTAL; Interventions: Drug: Golimumab, Drug: Placebo | Arm Label: Group V: IV Placebo + MTX; Type: PLACEBO_COMPARATOR; Interventions: Drug: Methotrexate, Drug: Placebo | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): Group I: 2mg/kg Golimumab + MTX, Group II: 2mg/kg Golimumab only, Group III: 4mg/kg Golimumab + MTX, Group IV: 4mg/kg Golimumab only | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Group I: 2mg/kg Golimumab + MTX, Group III: 4mg/kg Golimumab + MTX, Group V: IV Placebo + MTX | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group II: 2mg/kg Golimumab only, Group IV: 4mg/kg Golimumab only, Group V: IV Placebo + MTX
D: N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Metabolic Acidosis and Its Impact on Mineral Metabolism and Physical Performance in Renal Transplant Patients
Brief Summary: Acidosis (accumulation of acid in the body) may be an underrecognized problem in patients after renal transplantation. It may have consequences on physical performance due to negative effects on bone and muscle metabolism.

Therefore, the purpose of this study is

1. to determine the status of physical capacity and bone structure in renal transplant patients with metabolic acidosis
2. to study the effect of substituting base equivalents (citrate) on acid/base status of renal transplant patients with acidosis
3. to compare the status of physical capacity and bone structure in renal transplant patients with metabolic acidosis before and after substitution with citrate


Options:
A: Arm Label: Paricalcitol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paricalcitol | Arm Label: Matching placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Paricalcitol; Assigned to Arm(s): Paricalcitol | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Matching placebo
B: Arm Label: Parmidronate; Type: EXPERIMENTAL; Interventions: Drug: Pamidronate | Intervention Type: DRUG; Name: Pamidronate; Assigned to Arm(s): Parmidronate
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cholecalciferol | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Cholecalciferol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
D: Arm Label: Postassium citrate; Type: EXPERIMENTAL; Interventions: Drug: Potassium citrate | Arm Label: Potassium chloride; Type: ACTIVE_COMPARATOR; Interventions: Drug: Potassium chloride | Intervention Type: DRUG; Name: Potassium citrate; Assigned to Arm(s): Postassium citrate | Intervention Type: DRUG; Name: Potassium chloride; Assigned to Arm(s): Potassium chloride

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Phase 2 Trial Investigating Liposomal Doxorubicin With or Without Anti-Platelet Derived Growth Factor Receptor-Alpha (PDGFRα) Monoclonal Antibody IMC-3G3 in Patients With Platinum-Refractory or Platinum-Resistant Advanced Ovarian Cancer
Brief Summary: The purpose of this study is to determine if participants with platinum-refractory or platinum-resistant advanced ovarian cancer have a better outcome when treated with Olaratumab (IMC-3G3) in combination with Liposomal Doxorubicin than when treated with Liposomal Doxorubicin alone.


Options:
A: Arm Label: AMG 386; Type: EXPERIMENTAL; Interventions: Drug: AMG 386, Drug: Paclitaxel | Arm Label: AMG 386 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: AMG 386 Placebo, Drug: Paclitaxel | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): AMG 386 | Intervention Type: DRUG; Name: AMG 386 Placebo; Assigned to Arm(s): AMG 386 Placebo | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): AMG 386 | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): AMG 386 Placebo
B: Arm Label: Experimental; Type: EXPERIMENTAL; Interventions: Drug: Sorafenib | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): Experimental
C: Arm Label: BI 6727; Type: EXPERIMENTAL; Interventions: Drug: BI 6727 | Arm Label: Cytotoxic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Gemcitabine, Drug: Topotecan, Drug: Pegylated liposomal doxorubicin (PLD) | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Cytotoxic | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Cytotoxic | Intervention Type: DRUG; Name: Topotecan; Assigned to Arm(s): Cytotoxic | Intervention Type: DRUG; Name: Pegylated liposomal doxorubicin (PLD); Assigned to Arm(s): Cytotoxic | Intervention Type: DRUG; Name: BI 6727; Assigned to Arm(s): BI 6727
D: Arm Label: Olaratumab and Liposomal Doxorubicin; Type: EXPERIMENTAL; Interventions: Biological: Olaratumab, Drug: liposomal doxorubicin | Arm Label: Liposomal Doxorubicin: Optional Olaratumab Monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Biological: Olaratumab, Drug: liposomal doxorubicin | Intervention Type: BIOLOGICAL; Name: Olaratumab; Assigned to Arm(s): Liposomal Doxorubicin: Optional Olaratumab Monotherapy, Olaratumab and Liposomal Doxorubicin | Intervention Type: DRUG; Name: liposomal doxorubicin; Assigned to Arm(s): Liposomal Doxorubicin: Optional Olaratumab Monotherapy, Olaratumab and Liposomal Doxorubicin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Phase 2 Trial Investigating Liposomal Doxorubicin With or Without Anti-Platelet Derived Growth Factor Receptor-Alpha (PDGFRα) Monoclonal Antibody IMC-3G3 in Patients With Platinum-Refractory or Platinum-Resistant Advanced Ovarian Cancer
Brief Summary: The purpose of this study is to determine if participants with platinum-refractory or platinum-resistant advanced ovarian cancer have a better outcome when treated with Olaratumab (IMC-3G3) in combination with Liposomal Doxorubicin than when treated with Liposomal Doxorubicin alone.


Options:
A: Arm Label: Paclitaxel/Carboplatin/Sorafenib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sorafenib, Drug: Paclitaxel, Drug: Carboplatin | Arm Label: Paclitaxel/carboplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: Carboplatin | Intervention Type: DRUG; Name: Sorafenib; Assigned to Arm(s): Paclitaxel/Carboplatin/Sorafenib | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Paclitaxel/Carboplatin/Sorafenib, Paclitaxel/carboplatin | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Paclitaxel/Carboplatin/Sorafenib, Paclitaxel/carboplatin
B: Arm Label: Olaparib 300mg tablets; Type: EXPERIMENTAL; Interventions: Drug: Olaparib 300mg tablets | Arm Label: Placebo tablets; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to match olaparib 300mg | Intervention Type: DRUG; Name: Olaparib 300mg tablets; Assigned to Arm(s): Olaparib 300mg tablets | Intervention Type: DRUG; Name: Placebo to match olaparib 300mg; Assigned to Arm(s): Placebo tablets
C: Arm Label: Olaratumab and Liposomal Doxorubicin; Type: EXPERIMENTAL; Interventions: Biological: Olaratumab, Drug: liposomal doxorubicin | Arm Label: Liposomal Doxorubicin: Optional Olaratumab Monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Biological: Olaratumab, Drug: liposomal doxorubicin | Intervention Type: BIOLOGICAL; Name: Olaratumab; Assigned to Arm(s): Liposomal Doxorubicin: Optional Olaratumab Monotherapy, Olaratumab and Liposomal Doxorubicin | Intervention Type: DRUG; Name: liposomal doxorubicin; Assigned to Arm(s): Liposomal Doxorubicin: Optional Olaratumab Monotherapy, Olaratumab and Liposomal Doxorubicin
D: Arm Label: Olaparib; Type: EXPERIMENTAL; Interventions: Drug: Olaparib | Arm Label: Chemotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly | Intervention Type: DRUG; Name: Olaparib; Assigned to Arm(s): Olaparib | Intervention Type: DRUG; Name: carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly; Assigned to Arm(s): Chemotherapy

Answer: C